ODB lists Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin

//ODB lists Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin

ODB lists Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin

We are pleased to announce that Ontario Drug Benefit (ODB) has listed Afinitor (everolimus) for the treatment of patients with GI/Lung NET, effective November 20, 2017 through the Exceptional Access Program (EAP) with the following criteria:

Afinitor (everolimus): The Patient:

·        is at least 18 years old;
·        has unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL);
·        has documented radiological disease progression within the 6 months preceding the request; and
·        has a good performance status (i.e. ECOG 0-2).

 

ODB FORMULARY – EDITION NO. 42, Summary of Changes – November 2017

Summary of Changes – November 2017 to Edition No. 42 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective November 30, 2017. The updated Edition No. 42 document will be posted on the Ministry’s website http://www.health.gov.on.ca/en/pro/programs/drugs/edition_42.aspx by November 30, 2017.

Exceptional Access Program (EAP) Product

Afinitor (everolimus) 2.5mg, 5mg, 7.5mg, 10mg Tab (NOV) – Effective Date: November 20, 2017

For the treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) according to clinical criteria. The 7.5mg Tab is also a newly funded strength.

 

By | 2018-05-07T18:28:10+00:00 November 24th, 2017|News|0 Comments

About the Author:

Leave A Comment